JP2024510436A5 - - Google Patents

Info

Publication number
JP2024510436A5
JP2024510436A5 JP2023554337A JP2023554337A JP2024510436A5 JP 2024510436 A5 JP2024510436 A5 JP 2024510436A5 JP 2023554337 A JP2023554337 A JP 2023554337A JP 2023554337 A JP2023554337 A JP 2023554337A JP 2024510436 A5 JP2024510436 A5 JP 2024510436A5
Authority
JP
Japan
Prior art keywords
compound
degrees
approximately
treatment
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023554337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510436A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/020716 external-priority patent/WO2022197901A1/en
Publication of JP2024510436A publication Critical patent/JP2024510436A/ja
Publication of JP2024510436A5 publication Critical patent/JP2024510436A5/ja
Pending legal-status Critical Current

Links

JP2023554337A 2021-03-17 2022-03-17 大うつ病性障害の処置のための19-ノルc3,3-2置換c21-n-ピラゾリルステロイド Pending JP2024510436A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163162501P 2021-03-17 2021-03-17
US63/162,501 2021-03-17
US202163284592P 2021-11-30 2021-11-30
US63/284,592 2021-11-30
PCT/US2022/020716 WO2022197901A1 (en) 2021-03-17 2022-03-17 A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder

Publications (2)

Publication Number Publication Date
JP2024510436A JP2024510436A (ja) 2024-03-07
JP2024510436A5 true JP2024510436A5 (cg-RX-API-DMAC7.html) 2025-03-25

Family

ID=81327141

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023554337A Pending JP2024510436A (ja) 2021-03-17 2022-03-17 大うつ病性障害の処置のための19-ノルc3,3-2置換c21-n-ピラゾリルステロイド

Country Status (11)

Country Link
US (1) US20240245711A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308162A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024510436A (cg-RX-API-DMAC7.html)
KR (1) KR20230158033A (cg-RX-API-DMAC7.html)
AU (1) AU2022238365A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023018607A2 (cg-RX-API-DMAC7.html)
CA (1) CA3213744A1 (cg-RX-API-DMAC7.html)
IL (1) IL305858A (cg-RX-API-DMAC7.html)
MX (1) MX2023010728A (cg-RX-API-DMAC7.html)
TW (1) TW202300156A (cg-RX-API-DMAC7.html)
WO (1) WO2022197901A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) * 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
TW202604538A (zh) * 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3612186A1 (en) * 2017-04-18 2020-02-26 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CA3187178A1 (en) 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20230372364A1 (en) * 2020-10-01 2023-11-23 Jeremy Hill Method of treating gaba mediated disorders

Similar Documents

Publication Publication Date Title
IL305858A (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder
Dermaut et al. Prevalence of tooth agenesis correlated with jaw relationship and dental crowding
JP2020532531A5 (cg-RX-API-DMAC7.html)
JP2023076465A5 (cg-RX-API-DMAC7.html)
JP2024540183A5 (cg-RX-API-DMAC7.html)
Amin et al. Success rate of treatments provided for early childhood caries under general anesthesia: a retrospective cohort study
JP2022191257A5 (cg-RX-API-DMAC7.html)
JP2022537047A5 (cg-RX-API-DMAC7.html)
JP2015038149A5 (cg-RX-API-DMAC7.html)
JP2010535805A5 (cg-RX-API-DMAC7.html)
JP2022523726A5 (cg-RX-API-DMAC7.html)
JP2025508071A5 (cg-RX-API-DMAC7.html)
JPWO2023195530A5 (cg-RX-API-DMAC7.html)
JP2025502023A5 (cg-RX-API-DMAC7.html)
JP2022531251A5 (cg-RX-API-DMAC7.html)
NO20055000L (no) Fremgangsmate for a hindre varme oppblusinger ved anvendelse av prodrug av gaba-analoger
JP2024543379A5 (cg-RX-API-DMAC7.html)
JP2021532176A5 (cg-RX-API-DMAC7.html)
JP2025508051A5 (cg-RX-API-DMAC7.html)
JP2022550828A5 (cg-RX-API-DMAC7.html)
JP2023011549A5 (cg-RX-API-DMAC7.html)
JP2005513036A5 (cg-RX-API-DMAC7.html)
MX2025012741A (es) Composiciones farmaceuticas orales
JP2018531961A5 (cg-RX-API-DMAC7.html)
JP2023537369A5 (cg-RX-API-DMAC7.html)